Haleon Pakistan Ltd
Haleon Pakistan Ltd maintains a strong liquidity position, with a current ratio of 1.36, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score suggests a medium liquidity risk, which is consistent with its operating cash flow of PKR 3.25 billion and free cash flow of PKR 1.04 billion. However, the company's net cash position is negative after subtracting total debt, which may pose a liquidity challenge in the near term. In terms of profitability, Haleon Pakistan Ltd demonstrates a return on equity (ROE) of 12.36% and a return on assets (ROA) of 5.54%. These figures suggest the company is generating reasonable returns for its shareholders and effectively utilizing its assets. The company's operating income of PKR 2.09 billion and net income of PKR 1.22 billion further support its profitability. The debt-to-equity ratio of 0.02 indicates a conservative capital structure with minimal leverage. Geographically, Haleon Pakistan Ltd is primarily focused on the domestic market, with no disclosed international revenue segments. The company's revenue concentration in Pakistan may expose it to local economic and regulatory risks. The company's business is not segmented by product lines in the provided data, but its primary activity is in pharmaceuticals and medical research. Looking at the growth trajectory, the company's revenue for the latest period was PKR 9.81 billion. While the outlook for the current and next fiscal years is not explicitly provided, the company's capital expenditure of PKR -1.09 billion suggests a focus on cost management rather than expansion. The company's free cash flow of PKR 1.04 billion indicates it has the financial flexibility to support operations and potentially fund future growth initiatives. The risk assessment for Haleon Pakistan Ltd highlights a medium liquidity risk and a low dilution risk. The company's dilution potential is low, with no significant changes in shares outstanding between basic and diluted shares. The company's conservative capital structure and strong cash flow position it to manage its debt obligations effectively. However, the negative net cash position after subtracting total debt is a concern that may require monitoring. Recent events and filings for Haleon Pakistan Ltd do not include specific details in the provided data. Analyst estimates suggest a mean price target of PKR 1,134.00, with a median price target of PKR 1,134.00 and a recommendation mean of 2.50, indicating a neutral outlook. The company has one buy and one hold recommendation, with no strong buy recommendations.
Business. Haleon Pakistan Ltd operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of healthcare products.
Classification. The company is classified under the Healthcare economic sector and the Pharmaceuticals & Medical Research business sector with a confidence level of 0.92.
- Haleon Pakistan Ltd has a strong liquidity position with a current ratio of 1.36 and positive operating and free cash flows.
- The company's ROE of 12.36% and ROA of 5.54% indicate solid profitability and efficient asset utilization.
- The company's revenue is concentrated in Pakistan, which may expose it to local economic and regulatory risks.
- The company's capital expenditure is negative, suggesting a focus on cost management rather than expansion.
- The company has a low dilution risk, with no significant changes in shares outstanding.
- Analysts have a neutral outlook on the company, with a mean price target of PKR 1,134.00.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.